Holders — by stockHoldings — by fund
Lion Point Capital, LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001643354
$20.9M
disclosed book value
35
positions
8%
largest position share
Positions, as of 2026-06-30
top 35 of 35 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | CUECUE BIOPHARMA INC | 52,928 | $1.7M | 8% |
| 2 | PRAXPRAXIS PRECISION MEDICINES I | 4,450 | $1.5M | 7.1% |
| 3 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 67,500 | $1.3M | 6.3% |
| 4 | FENCFENNEC PHARMACEUTICALS INC | 112,434 | $1.2M | 5.8% |
| 5 | ROYALTY PHARMA PLC | 21,400 | $1.2M | 5.7% |
| 6 | CMPSCOMPASS PATHWAYS PLC | 80,000 | $1.1M | 5.4% |
| 7 | MISTMILESTONE PHARMACEUTICALS IN | 820,000 | $1.1M | 5.3% |
| 8 | BNTCBENITEC BIOPHARMA INC | 62,000 | $829,560 | 4% |
| 9 | SNDXSYNDAX PHARMACEUTICALS INC | 36,000 | $786,960 | 3.8% |
| 10 | BIOHAVEN LTD | 51,700 | $769,296 | 3.7% |
| 11 | GERNGERON CORP | 578,000 | $739,840 | 3.5% |
| 12 | UNIQURE NV | 14,700 | $677,082 | 3.2% |
| 13 | ARDXARDELYX INC | 128,650 | $656,115 | 3.1% |
| 14 | LNTHLANTHEUS HLDGS INC | 5,500 | $610,170 | 2.9% |
| 15 | IRONDISC MEDICINE INC | 8,100 | $592,434 | 2.8% |
| 16 | SRPTSAREPTA THERAPEUTICS INC | 28,500 | $512,145 | 2.4% |
| 17 | HUMAHUMACYTE INC | 650,000 | $507,260 | 2.4% |
| 18 | KURAKURA ONCOLOGY INC | 46,000 | $504,620 | 2.4% |
| 19 | VTRSVIATRIS INC | 27,700 | $439,876 | 2.1% |
| 20 | DYNDYNE THERAPEUTICS INC | 18,000 | $399,780 | 1.9% |
| 21 | BBIOBRIDGEBIO PHARMA INC | 5,000 | $372,400 | 1.8% |
| 22 | EWTXEDGEWISE THERAPEUTICS INC | 9,100 | $369,733 | 1.8% |
| 23 | PCRXPACIRA BIOSCIENCES INC | 13,500 | $342,495 | 1.6% |
| 24 | RGNXREGENXBIO INC | 26,600 | $318,668 | 1.5% |
| 25 | RCKTROCKET PHARMACEUTICALS INC | 86,000 | $294,120 | 1.4% |
| 26 | JANXJANUX THERAPEUTICS INC | 19,000 | $291,840 | 1.4% |
| 27 | MLYSMINERALYS THERAPEUTICS INC | 10,500 | $283,290 | 1.4% |
| 28 | GH RESEARCH PLC | 10,200 | $274,176 | 1.3% |
| 29 | MCRBSERES THERAPEUTICS INC | 31,570 | $249,087 | 1.2% |
| 30 | AZTAAZENTA INC | 9,700 | $247,544 | 1.2% |
| 31 | JSPRJASPER THERAPEUTICS INC | 465,000 | $195,765 | 0.9% |
| 32 | INVAINNOVIVA INC | 8,200 | $186,222 | 0.9% |
| 33 | IPHAINNATE PHARMA S A | 81,151 | $149,318 | 0.7% |
| 34 | ARQTARCUTIS BIOTHERAPEUTICS INC | 5,250 | $137,655 | 0.7% |
| 35 | SPRBSPRUCE BIOSCIENCES INC | 1,000 | $54,000 | 0.3% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.